Interaction between type 2 diabetes and past COVID-19 on active tuberculosis.

Publication date: Dec 04, 2024

The global setback in tuberculosis (TB) prevalence and mortality in the post-COVID-19 era has been partially attributed to pandemic-related disruptions in healthcare systems. The additional biological contribution of COVID-19 to TB is less clear. The goal of this study was to determine if there is an association between COVID-19 in the past 18 months and a new TB episode, and the role played by type 2 diabetes mellitus (DM) comorbidity in this relationship. A cross-sectional study was conducted among 112 new active TB patients and 373 non-TB controls, identified between June 2020 and November 2021 in communities along the Mexican border with Texas. Past COVID-19 was based on self-report or positive serology. Bivariable/multivariable analysis were used to evaluate the odds of new TB in hosts with past COVID-19 and/or DM status. The odds of new TB were higher among past COVID-19 cases vs. controls, but only significant among DM patients (aOR 2. 3). The odds of TB in people with DM was 2. 7-fold higher among participants without past COVID-19 and increased to 7. 9-fold among those with past COVID-19. DM interacts with past COVID-19 synergistically to magnify the risk of TB. Latent TB screening and prophylactic treatment, if positive, is recommended in past COVID-19 persons with DM. Future studies are warranted with a longitudinal design and larger sample size to confirm our findings.

Open Access PDF

Concepts Keywords
Diabetes Adult
Global Aged
June Comorbidity
Mexican COVID-19
November COVID-19
Cross-Sectional Studies
Cross-sectional study
Diabetes Mellitus, Type 2
Female
Humans
Male
Mexico
Mexico
Middle Aged
Prevalence
Risk Factors
SARS-CoV-2
Texas
Tuberculosis
Tuberculosis
Type 2 diabetes

Semantics

Type Source Name
disease MESH type 2 diabetes
disease MESH COVID-19
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO role
disease MESH comorbidity
disease MESH Long Covid
disease MESH Infectious Diseases
pathway REACTOME Reproduction
disease MESH diabetes mellitus
drug DRUGBANK Ribostamycin
disease MESH Obesity
disease IDO host
disease MESH infection
pathway REACTOME Immune System
disease MESH inflammation
disease MESH lymphopenia
disease MESH secondary infections
drug DRUGBANK Dextrose unspecified form
disease IDO history
disease MESH latent infection
drug DRUGBANK Gold
drug DRUGBANK BCG vaccine
disease MESH scarring
disease MESH hyperglycemia
disease MESH high blood pressure
disease MESH kidney disease
disease MESH underweight
disease MESH overweight
disease IDO blood
disease MESH marital status
disease MESH vascular disease
drug DRUGBANK Dextromethorphan
disease IDO cell
disease MESH cross infections
drug DRUGBANK Indoleacetic acid
disease MESH viral infection
disease MESH Allergy
drug DRUGBANK Honey
disease MESH death
disease MESH pneumonia
disease MESH pulmonary tuberculosis
drug DRUGBANK Proline
disease IDO assay

Original Article

(Visited 1 times, 1 visits today)